Comprehensive molecular profiling of 5,175 esophagogastric cancer (EGC) patients identified distinct molecular signatures for early-onset (< 50 years of age, EOEGC, n=530) versus average-onset (AOEGC, n=4,645) tumors.
EOEGC has increased frequency of CDH1 mutations, ARHGAP26 fusions, enrichment of epithelial mesenchymal transition (EMT) and angiogenesis pathways, decreased MAPK pathway activity, decreased frequency of TMB-high and dMMR/MSI-H, and a unique immune cell infiltrate with decreased M1 macrophages and increased M2 macrophages.
These unique differential characteristics present therapeutic opportunities but also demonstrate the limitations of currently approved therapies in this subset of patients.
Trastuzumab deruxtecan-nxki (T-DXd) was approved on April 5, 2024, by the US Food and Drug Administration for adults with unresectable or metastatic human epidermal growth… […]
Durable Response in NTRK Fusion-Positive Advanced Salivary Gland Tumor: A Case Report
Abstract Introduction:NTRK fusions lead to the production of constitutively active TRK proteins, which drive oncogenesis in approximately 0.2% of cancers. However, these fusions occur more frequently… […]
